In a report released on May 11, Christopher Liu from SVB Securities maintained a Hold rating on Monte Rosa Therapeutics (GLUE – Research Report), with a price target of $15.00. The company’s shares closed last Friday at $5.68.
Liu covers the Healthcare sector, focusing on stocks such as Cogent Biosciences, Arvinas Holding Company, and C4 Therapeutics. According to TipRanks, Liu has an average return of -18.7% and a 27.27% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Monte Rosa Therapeutics with a $21.20 average price target, a 273.24% upside from current levels. In a report released on May 12, Credit Suisse also reiterated a Hold rating on the stock with a $11.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
GLUE market cap is currently $280.4M and has a P/E ratio of -2.34.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Monte Rosa Therapeutics Inc is a biopharmaceutical company involved in developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to degrade therapeutically relevant proteins. It has developed a protein degradation platform, called QuEEN, that enables to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates.
Read More on GLUE:
- Monte Rosa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update
- Monte Rosa Therapeutics Presents Preclinical Data from GSPT1 Degrader Program Focused on MYC-Driven Cancers at AACR 2023
- Monte Rosa Therapeutics presents preclinical data from GSPT1 degrader program
- Monte Rosa Therapeutics Appoints Dr. Jan Skvarka to Board of Directors
- Monte Rosa Therapeutics appoints Jan Skvarka to board of directors
